Form 4 for SION Sionna Therapeutics, Inc.
Accepted 2026-09-18 16:58:01 ET · period of report 2026-09-17 · accession 0002046433-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-09-18 16:58 | 2026-09-17 | SION | McKee Charlotte | CMO, Head of R, D | A - Grant | $0.00 | +100.0K | 128.4K | +352% | $0 |
| D | 2026-09-18 16:58 | 2026-09-17 | SION | McKee Charlotte | CMO, Head of R, D | A - Grant | $0.00 | +155.7K | 155.7K | New | $0 |
| D | 2026-09-18 16:58 | 2026-09-17 | SION | McKee Charlotte | CMO, Head of R, D | D - Sale to Iss | $0.00 | -155.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-17 | A | A | 50,000 | $0.00 | 78,415 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date. |
| 2 | Common | Common Stock | 2026-09-17 | A | A | 50,000 | $0.00 | 128,415 | D | — | — | (F2) Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-09-17 | A | A | 155,700 | $0.00 | 155,700 | D | $7.18 · — to 2036-01-01 | 155,700 Common Stock | (F3) The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "2025 Plan")) or (iii) certain qualifying terminations of service. (F4) Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. (F4) Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. (F5) This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-09-17 | D | D | 155,700 | $0.00 | 0 | D | $39.21 · — to 2036-01-01 | 155,700 Common Stock | (F4) Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. (F4) Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. (F5) This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |